Skip to main content
Fig. 4 | BMC Complementary Medicine and Therapies

Fig. 4

From: Protective effect of silymarin on tacrolimus-induced kidney and liver toxicity

Fig. 4

 A Statistically significantly increased ALT level in the Tac group compared to the Tac + SLI 100 group (P < 0.05). B Significantly higher AST level in the Tac group compared to the other experimental study groups (P < 0.05). C High GGT level in the Tac and Tac + SLI 100 groups and low level in SLI 200 group (P < 0.05). D Non-statistically significant albumin level between the groups (P > 0.05). E Statistically significantly increased total bilirubin level in the Tac group (P < 0.05). F Statistically different creatine level in the Tac and Tac + SLI 100 groups compared to the other experimental groups (P < 0.05)

Back to article page